FLUAR - A novel solution for fluorescence-guided surgery based on augmented reality

FLUAR project aims to enhance tumor removal accuracy in cancer surgeries by developing AR glasses with integrated NIR sensors for real-time visualization of fluorescent biomarkers.

Subsidie
€ 2.458.000
2023

Projectdetails

Introduction

Fluorescence-guided surgery (FGS) uses near-infrared (NIR) sensors to detect and display fluorescent biomarkers indicating the exact location of tumors. However, the current cameras and monitors force surgeons to match the images to the body via subjective comparisons.

Problem Statement

This long, error-prone process reduces accuracy and increases operating times and costs. This is a critical problem in cancer surgery where complete tumor removal is key to preventing recurrence. For example, a yearly incidence of <0.5 million breast cancer patients requires over 2.8 million surgeries.

Solution Overview

FLUAR are novel augmented reality (AR) glasses with integrated high-end NIR sensors and computer vision algorithms. They detect and display the fluorescent biomarkers in the surgeon's direct sight, hence showing the tumor margins on the target.

Project Goals

FLUAR will increase the surgeon's accuracy and reduce tumor removal times. This project aims to finalize and validate FLUAR's technical developments and clinical usability according to end-user requirements.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.458.000
Totale projectbegroting€ 3.514.695

Tijdlijn

Startdatum1-4-2023
Einddatum31-3-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • ARSPECTRA S.A.R.L.penvoerder

Land(en)

Luxembourg

Vergelijkbare projecten binnen EIC Accelerator

EIC Accelerator

makinG aUgmedit lumI stanDArd in NeurosurgiCal surgEry in 3D: GUIDANCE 3D

Augmedit aims to revolutionize surgery with Lumi Elite, an AR SaaS that enhances surgical precision and safety by transforming 2D imaging into intuitive 3D holograms for better patient care.

€ 1.716.743
EIC Accelerator

SWAN: Blitzscaling the early detection of skin cancer

Swan offers rapid, full-body dermoscopic skin cancer detection using advanced AI and imaging technologies, enhancing early diagnosis and treatment accessibility for all stakeholders.

€ 2.500.000
EIC Accelerator

Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery

Thericon is developing an rMSI platform to enhance endoscopic cancer surgery by providing multi-parametric imaging for better tissue differentiation and reducing cancer recurrence, seeking funding for market launch in 2024.

€ 2.500.000

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Colouring the Dark in Fluorescence Light

CoDaFlight aims to develop a next-generation real-time fluorescence imaging platform to enhance surgical decision-making and address unmet clinical needs through innovative technology.

€ 2.999.300
Mkb-innovati...

SURgical eNhanced Image Augmented Reality (SURNIA)

SURNIA ontwikkelt een innovatieve chirurgische loep met augmented reality voor verbeterde precisie, training en real-time ondersteuning in operaties.

€ 198.065
ERC Proof of...

A Real-time imaging and classification system for low-grade glioma detection during brain surgery

This project aims to develop a real-time imaging tool for neurosurgeons to accurately identify low-grade glioma tissue during surgery, enhancing tumor removal and improving patient outcomes.

€ 150.000
EIC Pathfinder

Multimodal Hypersprectal Imaging and Raman Spectroscopy for Intraoperative Assessment of Breast Tumor Resection Margins

Spectra-BREAST aims to enhance tumor margin assessment in breast conserving surgery using a novel multimodal approach for real-time, accurate feedback, improving patient outcomes and reducing reoperation rates.

€ 2.990.207
EIC Pathfinder

Transforming brain surgery by advancing functional-guided neuronavigational imaging

HyperProbe is an innovative all-optical imaging system using hyperspectral imaging and AI to enhance intraoperative neuronavigation and biomarker analysis during brain tumor surgeries.

€ 3.360.825